Pain Sensitivity, Alcohol-Induced Analgesia, and Heavy Drinking in Individuals With Opioid Use Disorder
The goal of this clinical trial is to examine whether individuals with co-occurring opioid use disorder and alcohol use (OUD+ALC) experience heightened pain sensitivity, pain-related negative affect, and greater alcohol reinforcement compared with alcohol-only (ALC) or opioid-only (OUD-ALC) users.
The main questions it aims to answer are:
- Aim 1. Do individuals with OUD+ALC experience increased pain and pain-related negative affect during periods of sobriety relative to mono-users of alcohol (ALC only) and opioids (OUD-ALC)?
- Aim 2. Do individuals with OUD+ALC experience greater alcohol-induced analgesia and alcohol reinforcement compared with mono-users of alcohol (ALC only) and opioids (OUD-ALC)?
Participants will:
- Complete a screening session
- Complete one lab session including a comprehensive assessment battery involving multimodal assessments of pain during sobriety
- Complete two experimental lab sessions that will include intravenous (IV) administration of either 80mg% alcohol or placebo (saline), order counterbalanced, to measure alcohol's acute effects on pain and pain-related negative affect
Studie Overzicht
Toestand
Toestand
Conditie
Conditie
Interventie / Behandeling
Interventie / Behandeling
Studietype
Studietype
Inschrijving (Geschat)
Inschrijving
Fase
Fase
- Vroege fase 1
Contacten en locaties
Studiecontact
Studiecontact
- Naam: Stephanie Gorka, PhD
- Telefoonnummer: 614-366-1027
- E-mail: stephanie.gorka@osumc.edu
Studie Locaties
-
-
Ohio
-
Columbus, Ohio, Verenigde Staten, 43210
- Werving
- Ohio State University
-
Contact:
- Stephanie Gorka, PhD
- Telefoonnummer: 614-366-1027
- E-mail: stephanie.gorka@osumc.edu
-
-
Deelname Criteria
Geschiktheidscriteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
ALC Only Group:
- 21-65 years old
- Required to meet NIAAA criteria for heavy drinking (Male: Consuming 5 or more drinks on any day or 15 or more per week; Female: consuming 4 or more on any day or 8 or more drinks per week)
OUD + ALC Group:
- 21-65 years old
- Required to meet NIAAA criteria for heavy drinking (Male: Consuming 5 or more drinks on any day or 15 or more per week; Female: consuming 4 or more on any day or 8 or more drinks per week)
- Meet DSM-5 criteria for current opioid use disorder (OUD)
- Report using recreational opioids at least weekly (past month)
OUD-ALC Group:
- 21-65 years old
- Meet DSM-5 criteria for current OUD
- Report using recreational opioids at least weekly (past month)
- Meet "light drinking" criteria (consuming equal to or less than 4 drinks per week for women or consuming equal to or less than 5 drinks per week for men)
- Report at least 1 but no more than 3 binge episodes over the past 12 months
Exclusion Criteria:
- Serious medical problems
- Current medical or psychiatric conditions requiring medication for which alcohol is contraindicated (including prescription opioids)
- Any serious medical problems
- Sensitivity or allergy to alcohol
- Body weight < 110 or > 210 lbs for alcohol administration
- Injury, trauma, nerve/tissue damage, or deformity prohibiting sensory testing
- Moderate to severe substance use disorders other than alcohol use disorder (AUD) or OUD
- Current severe mental illness, including mania or psychosis
- Currently seeking inpatient/intensive treatment for addictive behaviors
- Pregnant or nursing and unwilling to take measures to avoid becoming pregnant during the study (females)
- Chronic pain requiring ongoing pain management within the past three months.
- Clinically significant alcohol or opioid withdrawal symptoms the day of the lab sessions, defined as a score >10 on the Clinical Institute Withdrawal Assessment of Alcohol Scale Revised (CIWA-Ar) or a score >12 on the Clinical Opioid Withdrawal Scale (COWS)
- Positive alcohol breath test or opioid urine screen the day of the experimental lab sessions to avoid the potential for alcohol-opioid interactions.
- Smoking more than 6 cigarettes per day (or alternative form equivalent)
- Not fluent in English
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Fundamentele wetenschap
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Crossover-opdracht
- Masker: Dubbele
Aantal wapens
Wapens en interventies
Deelnemersgroep / ArmDeelnemersgroep / Arm |
Interventie / BehandelingInterventie / Behandeling |
|---|---|
|
Ander: Alcohol (ALC) Only Group
Participants in this group will be required to meet the National Institute on Alcohol Abuse and Alcoholism (NIAAA) criteria for heavy drinking (Male: Consuming 5 or more drinks on any day or 15 or more per week; Female: consuming 4 or more on any day or 8 or more drinks per week). |
Participants will receive 80 mg% intravenous alcohol and saline. Participants receive placebo (saline) intravenously. |
|
Ander: Opioid Use Disorder (OUD) + ALC Group
Participants in this group will be required to 1) Meet the National Institute on Alcohol Abuse and Alcoholism (NIAAA) criteria for heavy drinking (Male: Consuming 5 or more drinks on any day or 15 or more per week; Female: consuming 4 or more on any day or 8 or more drinks per week); 2) Meet DSM-5 criteria for current OUD and; 3) Report using recreational opioids at least weekly (past month). |
Participants will receive 80 mg% intravenous alcohol and saline. Participants receive placebo (saline) intravenously. |
|
Ander: OUD-ALC Group
Participants in this group will be required to 1) Meet DSM-5 criteria for current OUD; 2) Report using recreational opioids at least weekly (past month); 3) Meet "light drinking" criteria (consuming less than or equal to 4 alcoholic drinks per week (female) or less than or equal to 5 alcoholic drinks (men) and; 4) Report at least 1 but no more than 3 binge episodes over the past 12 months. |
Participants will receive 80 mg% intravenous alcohol and saline. Participants receive placebo (saline) intravenously. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Pain intensity during the pressure task, measured using a visual analog scale (VAS)
Tijdsspanne: Baseline (Visit 1), approximately 7 days later (Visit 2), and approximately 14 days after baseline (Visit 3)
|
Pain intensity will be reported during the pressure task administered during each of the three laboratory sessions (Baseline, Placebo, and Alcohol). Participants will rate their perceived pain intensity using a numerical rating scale ranging from 0-100. |
Baseline (Visit 1), approximately 7 days later (Visit 2), and approximately 14 days after baseline (Visit 3)
|
|
Pain pressure threshold during the pressure task
Tijdsspanne: Baseline (Visit 1), approximately 7 days later (Visit 2), and approximately 14 days after baseline (Visit 3)
|
Pain pressure threshold is estimated by averaging reports across the different runs of the pressure task that is administered at all three lab sessions. |
Baseline (Visit 1), approximately 7 days later (Visit 2), and approximately 14 days after baseline (Visit 3)
|
|
Startle eyeblink potentiation during the anticipation task
Tijdsspanne: Baseline (Visit 1), approximately 7 days later (Visit 2), and approximately 14 days after baseline (Visit 3)
|
Startle eyeblink potentiation will be collected during the anticipation task that is administered at all three lab sessions. Startle is a cross-species index of aversive reactivity. |
Baseline (Visit 1), approximately 7 days later (Visit 2), and approximately 14 days after baseline (Visit 3)
|
|
Self-reported affect during the anticipation task
Tijdsspanne: Baseline (Visit 1), approximately 7 days later (Visit 2), and approximately 14 days after baseline (Visit 3)
|
At the end of the anticipation task, participants will rate how intense, arousing, and anxiety-provoking the task was on a 1-to-10 scale, with 1 indicating low intensity, arousal, or anxiety and 10 indicating high intensity, arousal, or anxiety. |
Baseline (Visit 1), approximately 7 days later (Visit 2), and approximately 14 days after baseline (Visit 3)
|
|
Subjective affective response to alcohol in the lab
Tijdsspanne: Placebo and Alcohol sessions (Visits 2 and 3), approximately 7 days apart.
|
Participants will complete the Profile of Mood States (POMS) throughout the placebo and alcohol administration protocols. The individual mood states will be examined and compared across sessions. Higher scores on each POMS subscale indicate a greater degree of the corresponding mood state, while lower scores indicate a lesser degree of that mood state. |
Placebo and Alcohol sessions (Visits 2 and 3), approximately 7 days apart.
|
Secundaire uitkomstmaten
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Subjective effects of alcohol in the lab
Tijdsspanne: Placebo and Alcohol sessions (Visits 2 and 3), approximately 7 days apart.
|
Participants will rate the degree to which they "feel", "like", and "want more" of the infused substance on a visual analog scale ranging from 0 to 100. The "like" and "want more" scales will serve as the primary measures of alcohol liking and wanting, respectively. |
Placebo and Alcohol sessions (Visits 2 and 3), approximately 7 days apart.
|
Medewerkers en onderzoekers
Sponsor
Sponsor
Medewerkers
Medewerkers
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Studie start
Primaire voltooiing (Geschat)
Primaire voltooiing
Studie voltooiing (Geschat)
Studie voltooiing
Studieregistratiedata
Eerst ingediend
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Eerst geplaatst
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update geplaatst
Laatste update ingediend die voldeed aan QC-criteria
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Narcotica-gerelateerde aandoeningen
- Neurologische manifestaties
- Psychische aandoening
- Middelgerelateerde aandoeningen
- Chemisch veroorzaakte aandoeningen
- Aan alcohol gerelateerde aandoeningen
- Pathologische aandoeningen, tekenen en symptomen
- Tekenen en symptomen
- Pijn
- Aan opioïden gerelateerde aandoeningen
- Alcoholische intoxicatie
- Organische chemicaliën
- Alcohol
- Ethanol
Andere studie-ID-nummers
Andere studie-ID-nummers
- STUDY20252506
- 1R21AA032964-01 (Subsidie/contract van de Amerikaanse NIH)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
De-identified data, including startle eyeblink and behavior, from this project will be submitted to the The National Institute on Alcohol Abuse and Alcoholism Data Archive (NIAAADA) at the subject level along with appropriate supporting documentation to enable efficient use of the data by the research community. We will follow instructions as discussed in the NDA Data Sharing Terms and Conditions.
IPD-tijdsbestek voor delen
The data will be submitted biannually.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .